Canada markets closed

CERo Therapeutics Holdings, Inc. (CERO)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.3799+0.0203 (+5.65%)
At close: 04:00PM EDT
0.3500 -0.03 (-7.87%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.3596
Open0.3480
Bid0.3700 x 200
Ask0.3800 x 100
Day's Range0.3400 - 0.4133
52 Week Range0.3300 - 12.8000
Volume4,584,662
Avg. Volume1,160,333
Market Cap5.722M
Beta (5Y Monthly)-0.20
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

    Company anticipates near term filing of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announced it successfully executed pre-IND manufacturing activities for its lead therapeutic, CER-1236. The completion of multiple manufacturing runs i

  • ACCESSWIRE

    Manitoba Woman Beats Stage 4 Cancer with Breakthrough CAR T-Cell Therapy

    VANCOUVER, BC / ACCESSWIRE / June 6, 2024 / Cancer treatments have come a long way over the years, but there is a newer treatment that is providing even stage four cancer patients with a new lease on life. Source: PexelsThe first CAR T-cell therapy ...

  • GlobeNewswire

    CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236

    Company continuing IND-enabling activities in preparation for submission of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces the successful completion of toxicology studies for its lead compound, CER-1236. The toxicology studies w